immunology, disease & medicine, clinical trials

Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.

Recent data show that the drug bamlanivimab, also known as LY-CoV555, does not appear to help those with severe cases of COVID-19, but trials continue for milder cases.

The company voluntarily paused its studies, including one in Phase 3, after an unexplained illness in a patient.

Eli Lilly reports a 72 percent reduction in hospitalization risk among patients who received its monoclonal antibody compared to those who received a placebo.

A randomized controlled trial on the use of convalescent plasma therapy to treat coronavirus infections—the first in the world to be completed—yields disappointing results, but some doctors are not discouraged.

The cholesterol-lowering drugs quell inflammation and reverse endothelial tissue damage, hints that they might curb the body’s excessive immune response to SARS-CoV-2 infection.

The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.

Although the oral treatment seems to work, an analysis of the results from 12 clinical trials finds kids who got an immunotherapy have a greater rate of serious reactions.

The promise of immunotherapy is real. We now need to figure out how to maximize the number of patients the approach benefits.